Baxter   2Q Revenues: $3.7 billion (+3%) 2Q Earnings: $590 million (-11%) YTD Revenues: $7.1 billion (+2%) YTD Earnings: $1.1 billion (-9%) Comments: BioScience revenues were $1.6 billion in the quarter (+5%), driven by hemophilia therapies ADVATE and FEIBA, as well as specialty plasma-based therapeutics and vaccines. Medical Products sales were $2.0 billion (+1%). Second quarter results include after-tax special items totaling $49 million, primarily for costs associated the planned acquisit...